Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of fostamatinib in methotrexate-inadequate responder rheumatoid arthritis in Asia
jRCT2080221801Phase 2
- Sponsor
- AstraZeneca
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fostamatinib in rheumatoid arthritis (RA) (5 arms), sponsored by AstraZeneca.
02
Drugs
fostamatinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080221801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221801.